

PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2026

PUNE, INDIA, March 9, 2018

/EINPresswire.com/ --

WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals"

Multiple Sclerosis

Overview

Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide.

In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of MS remains incompletely elucidated, but it is believed to involve a complex interaction between various environmental and genetic factors.

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/3031251-pharmapoint-multiple-sclerosis-global-drug-forecast-and-market-analysis-to-2026>



Companies mentioned

Bayer

Biogen

Merck KGaA

Teva

Sanofi

Novartis

Roche

Actelion

Celgene

Major Highlight of the Report

The late-stage candidates include products from both established and emerging players with a wide range of mechanism of action (MOA). Progressive MS is a significant focus for product development, with 8 of the late-stage products targeting this patient group as an initial indication, such as protecting mitochondrial energy sources (idebenone), antioxidants (MD1003), promoting remyelination (opicinumab) and neuroprotection (ibudilast and laquinimod). There is currently a distinct lack of DMT options for patients with progressive MS subtypes, and patients remain significantly underserved. The majority of the Phase III candidates targeting RRMS are based on established MOAs, such as second generation S1P receptor modulators (ozanimod and ponesimod) or anti-CD20 mAbs (ofatumumab and ublituximab).

Multiple Sclerosis Major Outlook

Overview of MS: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized MS market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, PPMS and SPMS), forecast from 2016 to 2026.

Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. Promising candidates in Phase IIB or above were profiled.

Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Multiple Sclerosis - Competitive Analysis

Key players are making innovative developments in Multiple Sclerosis. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/3031251-pharmapoint-multiple-sclerosis-global-drug-forecast-and-market-analysis-to-2026>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT

Wise Guy Reports

+91 841 198 5042

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.